Remove 2022 Remove Hospitals Remove Medication Labelling
article thumbnail

FDA Mandates Major Opioid Label Revisions to Highlight Long-Term Risks

Pharmacy Times

Labels now emphasize the risks of higher doses and caution against abrupt discontinuation in dependent patients to prevent withdrawal and other harms. Expanded warnings include interactions with CNS depressants and rare outcomes like esophageal dysfunction, aligning with CDC's 2022 opioid prescribing guidelines. REFERENCES 1.

article thumbnail

Five for Friday February 24: Celebrating Success in Advancing Medication Use Quality

PQA

-- Richard Schmitz, PQA Chief Engagement Officer Investigating Impact of Discontinuation Rates for Oral Oncolytics Results from a Walgreens study show that increased medication adherence on cycled oral antineoplastics can lead to lower medical costs and fewer hospitalization events compared with lower adherence levels.